Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Results from the Super Cryogenic Dark Matter Search Experiment at Soudan.

Agnese R, Aramaki T, Arnquist IJ, Baker W, Balakishiyeva D, Banik S, Barker D, Basu Thakur R, Bauer DA, Binder T, Bowles MA, Brink PL, Bunker R, Cabrera B, Caldwell DO, Calkins R, Cartaro C, Cerdeño DG, Chang Y, Chen Y, Cooley J, Cornell B, Cushman P, Daal M, Di Stefano PCF, Doughty T, Fascione E, Figueroa-Feliciano E, Fritts M, Gerbier G, Germond R, Ghaith M, Godfrey GL, Golwala SR, Hall J, Harris HR, Hong Z, Hoppe EW, Hsu L, Huber ME, Iyer V, Jardin D, Jastram A, Jena C, Kelsey MH, Kennedy A, Kubik A, Kurinsky NA, Loer B, Lopez Asamar E, Lukens P, MacDonell D, Mahapatra R, Mandic V, Mast N, Miller EH, Mirabolfathi N, Mohanty B, Morales Mendoza JD, Nelson J, Orrell JL, Oser SM, Page K, Page WA, Partridge R, Penalver Martinez M, Pepin M, Phipps A, Poudel S, Pyle M, Qiu H, Rau W, Redl P, Reisetter A, Reynolds T, Roberts A, Robinson AE, Rogers HE, Saab T, Sadoulet B, Sander J, Schneck K, Schnee RW, Scorza S, Senapati K, Serfass B, Speller D, Stein M, Street J, Tanaka HA, Toback D, Underwood R, Villano AN, von Krosigk B, Welliver B, Wilson JS, Wilson MJ, Wright DH, Yellin S, Yen JJ, Young BA, Zhang X, Zhao X; SuperCDMS Collaboration.

Phys Rev Lett. 2018 Feb 9;120(6):061802. doi: 10.1103/PhysRevLett.120.061802.

2.

Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo.

Lam M, Mast N, Pikuleva IA.

Mol Pharmacol. 2018 Feb;93(2):101-108. doi: 10.1124/mol.117.110742. Epub 2017 Nov 30.

PMID:
29192124
3.

Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).

Mast N, Lin JB, Anderson KW, Bjorkhem I, Pikuleva IA.

PLoS One. 2017 Oct 26;12(10):e0187168. doi: 10.1371/journal.pone.0187168. eCollection 2017. Erratum in: PLoS One. 2018 Jan 5;13(1):e0191058.

4.

Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Mast N, Saadane A, Valencia-Olvera A, Constans J, Maxfield E, Arakawa H, Li Y, Landreth G, Pikuleva IA.

Neuropharmacology. 2017 Sep 1;123:465-476. doi: 10.1016/j.neuropharm.2017.06.026. Epub 2017 Jun 24.

PMID:
28655608
5.

In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.

Mast N, Anderson KW, Johnson KM, Phan TTN, Guengerich FP, Pikuleva IA.

J Biol Chem. 2017 Aug 4;292(31):12934-12946. doi: 10.1074/jbc.M117.794909. Epub 2017 Jun 22.

PMID:
28642370
6.

Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Mast N, Anderson KW, Lin JB, Li Y, Turko IV, Tatsuoka C, Bjorkhem I, Pikuleva IA.

J Biol Chem. 2017 Mar 24;292(12):4913-4924. doi: 10.1074/jbc.M116.774760. Epub 2017 Feb 11.

7.

Retinal Hypercholesterolemia Triggers Cholesterol Accumulation and Esterification in Photoreceptor Cells.

Saadane A, Mast N, Dao T, Ahmad B, Pikuleva IA.

J Biol Chem. 2016 Sep 23;291(39):20427-39. doi: 10.1074/jbc.M116.744656. Epub 2016 Aug 11.

8.

Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.

Anderson KW, Mast N, Hudgens JW, Lin JB, Turko IV, Pikuleva IA.

J Biol Chem. 2016 May 27;291(22):11876-86. doi: 10.1074/jbc.M116.723577. Epub 2016 Apr 7.

9.

New Results from the Search for Low-Mass Weakly Interacting Massive Particles with the CDMS Low Ionization Threshold Experiment.

Agnese R, Anderson AJ, Aramaki T, Asai M, Baker W, Balakishiyeva D, Barker D, Basu Thakur R, Bauer DA, Billard J, Borgland A, Bowles MA, Brink PL, Bunker R, Cabrera B, Caldwell DO, Calkins R, Cerdeno DG, Chagani H, Chen Y, Cooley J, Cornell B, Cushman P, Daal M, Di Stefano PC, Doughty T, Esteban L, Fallows S, Figueroa-Feliciano E, Ghaith M, Godfrey GL, Golwala SR, Hall J, Harris HR, Hofer T, Holmgren D, Hsu L, Huber ME, Jardin D, Jastram A, Kamaev O, Kara B, Kelsey MH, Kennedy A, Leder A, Loer B, Lopez Asamar E, Lukens P, Mahapatra R, Mandic V, Mast N, Mirabolfathi N, Moffatt RA, Morales Mendoza JD, Oser SM, Page K, Page WA, Partridge R, Pepin M, Phipps A, Prasad K, Pyle M, Qiu H, Rau W, Redl P, Reisetter A, Ricci Y, Roberts A, Rogers HE, Saab T, Sadoulet B, Sander J, Schneck K, Schnee RW, Scorza S, Serfass B, Shank B, Speller D, Toback D, Underwood R, Upadhyayula S, Villano AN, Welliver B, Wilson JS, Wright DH, Yellin S, Yen JJ, Young BA, Zhang J; SuperCDMS Collaboration.

Phys Rev Lett. 2016 Feb 19;116(7):071301. doi: 10.1103/PhysRevLett.116.071301. Epub 2016 Feb 17.

10.

Cholesterol in mouse retina originates primarily from in situ de novo biosynthesis.

Lin JB, Mast N, Bederman IR, Li Y, Brunengraber H, Björkhem I, Pikuleva IA.

J Lipid Res. 2016 Feb;57(2):258-64. doi: 10.1194/jlr.M064469. Epub 2015 Dec 2.

11.

Cholesterol hydroperoxides as substrates for cholesterol-metabolizing cytochrome P450 enzymes and alternative sources of 25-hydroxycholesterol and other oxysterols.

van Lier JE, Mast N, Pikuleva IA.

Angew Chem Int Ed Engl. 2015 Sep 14;54(38):11138-42. doi: 10.1002/anie.201505002. Epub 2015 Jul 29.

12.

Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice.

Anderson KW, Mast N, Pikuleva IA, Turko IV.

FEBS Open Bio. 2015 Jun 25;5:550-6. doi: 10.1016/j.fob.2015.06.009. eCollection 2015.

13.

Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.

Mast N, Lin JB, Pikuleva IA.

Mol Pharmacol. 2015 Sep;88(3):428-36. doi: 10.1124/mol.115.099598. Epub 2015 Jun 16.

14.

Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.

Anderson KW, Chen J, Wang M, Mast N, Pikuleva IA, Turko IV.

PLoS One. 2015 May 11;10(5):e0126592. doi: 10.1371/journal.pone.0126592. eCollection 2015.

15.

Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments.

Zheng W, Mast N, Saadane A, Pikuleva IA.

J Lipid Res. 2015 Jan;56(1):81-97. doi: 10.1194/jlr.M053439. Epub 2014 Oct 7.

16.

Retinal and nonocular abnormalities in Cyp27a1(-/-)Cyp46a1(-/-) mice with dysfunctional metabolism of cholesterol.

Saadane A, Mast N, Charvet CD, Omarova S, Zheng W, Huang SS, Kern TS, Peachey NS, Pikuleva IA.

Am J Pathol. 2014 Sep;184(9):2403-19. doi: 10.1016/j.ajpath.2014.05.024. Epub 2014 Jul 25.

17.

Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain.

Saeed AA, Genové G, Li T, Lütjohann D, Olin M, Mast N, Pikuleva IA, Crick P, Wang Y, Griffiths W, Betsholtz C, Björkhem I.

J Biol Chem. 2014 Aug 22;289(34):23712-22. doi: 10.1074/jbc.M114.556159. Epub 2014 Jun 27.

18.

Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.

Mast N, Li Y, Linger M, Clark M, Wiseman J, Pikuleva IA.

J Biol Chem. 2014 Feb 7;289(6):3529-38. doi: 10.1074/jbc.M113.532846. Epub 2013 Dec 18.

19.

Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.

Mast N, Zheng W, Stout CD, Pikuleva IA.

Mol Pharmacol. 2013 Jul;84(1):86-94. doi: 10.1124/mol.113.085902. Epub 2013 Apr 19.

20.

Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response.

Mast N, Zheng W, Stout CD, Pikuleva IA.

J Biol Chem. 2013 Feb 15;288(7):4613-24. doi: 10.1074/jbc.M112.438754. Epub 2013 Jan 3.

21.

Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.

Mast N, Linger M, Pikuleva IA.

Mol Cell Endocrinol. 2013 May 22;371(1-2):100-6. doi: 10.1016/j.mce.2012.10.013. Epub 2012 Oct 23.

22.

Potential contribution of femoroacetabular impingement to recurrent traumatic hip dislocation.

Manner HM, Mast NH, Ganz R, Leunig M.

J Pediatr Orthop B. 2012 Nov;21(6):574-8. doi: 10.1097/BPB.0b013e328357bf04.

PMID:
22871962
23.

In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.

Mast N, Linger M, Clark M, Wiseman J, Stout CD, Pikuleva IA.

Mol Pharmacol. 2012 Nov;82(5):824-34. doi: 10.1124/mol.112.080424. Epub 2012 Aug 2.

24.

Abnormal vascularization in mouse retina with dysregulated retinal cholesterol homeostasis.

Omarova S, Charvet CD, Reem RE, Mast N, Zheng W, Huang S, Peachey NS, Pikuleva IA.

J Clin Invest. 2012 Aug;122(8):3012-23. doi: 10.1172/JCI63816. Epub 2012 Jul 23.

25.

Arthroscopic appearance and treatment of impingement cysts at femoral head-neck junction.

Leunig M, Mast NH, Impellizerri FM, Ganz R, Panaro C.

Arthroscopy. 2012 Jan;28(1):66-73. doi: 10.1016/j.arthro.2011.07.010. Epub 2011 Oct 19.

PMID:
22014697
26.

Revision total hip arthroplasty performed through the Hueter interval.

Mast NH, Laude F.

J Bone Joint Surg Am. 2011 May;93 Suppl 2:143-8. doi: 10.2106/JBJS.J.01736.

PMID:
21543704
27.

Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells.

Heo GY, Bederman I, Mast N, Liao WL, Turko IV, Pikuleva IA.

J Lipid Res. 2011 Jun;52(6):1117-27. doi: 10.1194/jlr.M014217. Epub 2011 Mar 16.

28.

Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1.

Mast N, Annalora AJ, Lodowski DT, Palczewski K, Stout CD, Pikuleva IA.

J Biol Chem. 2011 Feb 18;286(7):5607-13. doi: 10.1074/jbc.M110.188433. Epub 2010 Dec 15.

29.

Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain.

Liao WL, Heo GY, Dodder NG, Reem RE, Mast N, Huang S, Dipatre PL, Turko IV, Pikuleva IA.

J Proteome Res. 2011 Jan 7;10(1):241-8. doi: 10.1021/pr1008898. Epub 2010 Nov 16.

30.

Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.

Driscoll MD, McLean KJ, Levy C, Mast N, Pikuleva IA, Lafite P, Rigby SE, Leys D, Munro AW.

J Biol Chem. 2010 Dec 3;285(49):38270-82. doi: 10.1074/jbc.M110.164293. Epub 2010 Sep 30.

31.

Cholestenoic Acid is an important elimination product of cholesterol in the retina: comparison of retinal cholesterol metabolism with that in the brain.

Mast N, Reem R, Bederman I, Huang S, DiPatre PL, Bjorkhem I, Pikuleva IA.

Invest Ophthalmol Vis Sci. 2011 Feb 1;52(1):594-603. doi: 10.1167/iovs.10-6021. Print 2011 Jan.

32.

Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.

Mast N, Charvet C, Pikuleva IA, Stout CD.

J Biol Chem. 2010 Oct 8;285(41):31783-95. doi: 10.1074/jbc.M110.143313. Epub 2010 Jul 28.

33.

Reliability and agreement of measures used in radiographic evaluation of the adult hip.

Mast NH, Impellizzeri F, Keller S, Leunig M.

Clin Orthop Relat Res. 2011 Jan;469(1):188-99. doi: 10.1007/s11999-010-1447-9. Epub 2010 Jul 2.

34.

Marked variability in hepatic expression of cytochromes CYP7A1 and CYP27A1 as compared to cerebral CYP46A1. Lessons from a dietary study with omega 3 fatty acids in hamsters.

Mast N, Shafaati M, Zaman W, Zheng W, Prusak D, Wood T, Ansari GA, Lövgren-Sandblom A, Olin M, Bjorkhem I, Pikuleva I.

Biochim Biophys Acta. 2010 Jun;1801(6):674-81. doi: 10.1016/j.bbalip.2010.03.005. Epub 2010 Mar 16.

35.

The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection.

McLean KJ, Lafite P, Levy C, Cheesman MR, Mast N, Pikuleva IA, Leys D, Munro AW.

J Biol Chem. 2009 Dec 18;284(51):35524-33. doi: 10.1074/jbc.M109.032706.

36.

Simultaneous bilateral supine anterior approach total hip arthroplasty: evaluation of early complications and short-term rehabilitation.

Mast NH, Muñoz M, Matta J.

Orthop Clin North Am. 2009 Jul;40(3):351-6. doi: 10.1016/j.ocl.2009.04.002.

PMID:
19576402
37.

The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.

Shafaati M, Mast N, Beck O, Nayef R, Heo GY, Björkhem-Bergman L, Lütjohann D, Björkhem I, Pikuleva IA.

J Lipid Res. 2010 Feb;51(2):318-23. doi: 10.1194/jlr.M900174-JLR200. Epub 2009 May 27.

38.

Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.

Liao WL, Dodder NG, Mast N, Pikuleva IA, Turko IV.

Biochemistry. 2009 May 19;48(19):4150-8. doi: 10.1021/bi900168m.

39.

Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.

Mast N, Liao WL, Pikuleva IA, Turko IV.

Arch Biochem Biophys. 2009 Mar 1;483(1):81-9. doi: 10.1016/j.abb.2009.01.002. Epub 2009 Jan 10.

40.

Studies of membrane topology of mitochondrial cholesterol hydroxylases CYPs 27A1 and 11A1.

Pikuleva IA, Mast N, Liao WL, Turko IV.

Lipids. 2008 Dec;43(12):1127-32. doi: 10.1007/s11745-008-3234-x. Epub 2008 Sep 13.

41.

Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.

Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9546-51. doi: 10.1073/pnas.0803717105. Epub 2008 Jul 9.

42.

Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1.

White MA, Mast N, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA.

Acta Crystallogr D Biol Crystallogr. 2008 May;64(Pt 5):487-95. doi: 10.1107/S0907444908004046. Epub 2008 Apr 19.

43.

Validation of a genu valgum model in a rabbit hind limb.

Mast N, Brown NA, Brown C, Stevens PM.

J Pediatr Orthop. 2008 Apr-May;28(3):375-80. doi: 10.1097/BPO.0b013e318168c776.

PMID:
18362807
44.

Distinct binding of cholesterol and 5beta-cholestane-3alpha,7alpha,12alpha-triol to cytochrome P450 27A1: evidence from modeling and site-directed mutagenesis studies.

Mast N, Murtazina D, Liu H, Graham SE, Bjorkhem I, Halpert JR, Peterson J, Pikuleva IA.

Biochemistry. 2006 Apr 11;45(14):4396-404.

PMID:
16584175
45.

A simple and rapid method to measure cholesterol binding to P450s and other proteins.

Mast N, Pikuleva IA.

J Lipid Res. 2005 Jul;46(7):1561-8. Epub 2005 Apr 16.

46.

Cholesterol binding to cytochrome P450 7A1, a key enzyme in bile acid biosynthesis.

Mast N, Graham SE, Andersson U, Bjorkhem I, Hill C, Peterson J, Pikuleva IA.

Biochemistry. 2005 Mar 8;44(9):3259-71.

PMID:
15736936
47.

Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N- and C-terminal modifications.

Mast N, Andersson U, Nakayama K, Bjorkhem I, Pikuleva IA.

Arch Biochem Biophys. 2004 Aug 1;428(1):99-108.

PMID:
15234274
48.

Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.

Mast N, Norcross R, Andersson U, Shou M, Nakayama K, Bjorkhem I, Pikuleva IA.

Biochemistry. 2003 Dec 9;42(48):14284-92.

PMID:
14640697
49.

Revealing of proteins interacting with Na,K-ATPase.

Akimova OA, Dolgova NV, Mast NV, Rubtsov AM, Lopina OD.

Biochemistry (Mosc). 2003 Sep;68(9):1040-7.

PMID:
14606949
50.

Proteins binding to alpha1beta1 isozyme of Na,K-ATPase.

Dolgova N, Mast N, Akimova O, Rubtsov A, Lopina O.

Ann N Y Acad Sci. 2003 Apr;986:527-9. No abstract available.

PMID:
12763877

Supplemental Content

Support Center